Strategic Report Overview Highlights Strongest financial performance since the Groups Whats inside formation: well-positioned for future growth Strategic Report 2015 highlights Overview Highlights 1 Net assets increased by Net Assets approximately 50% to Group at a Glance 2 m 781.9m 2014: 526.2m Our Business & Strategy 781.9 178.8m net of expenses Chairmans letter 6 raised through the issue Marketplace 8 526.2 of new equity capital Business model 10 336.6 263.1 Acceleration of US Strategy 12 221.6 activities with four new 781.9m Our Performance 2014: 526.2m portfolio companies Key performance indicators 14 created bringing the total Operational review 16 2011 2012 2013 2014 2015 portfolio to five Portfolio review 18 Acquisition of a Financial review 30 40.0m strategic holding in Oxford Risk management 34 Share price performance Sciences Innovation plc, Building a sustainable business 42 m broadening the Groups exposure to spin-out 21% 0% Our Governance 205.0 companies from the 42% University of Oxford Overview Board of Directors 48 Modern Biosciences 53% plc reached the first Corporate Governance 50 78.2 development-related Committee Reports 0% milestones in its 2014: 21% Directors Remuneration Report 62 agreement with Janssen Report of the Audit and Biotech, Inc. triggering 2011 2012 2013 2014 2015 Risk Committee 87 gross payments of 8.0m Other Statutory Directors report 91 Statement of Directors Financial highlights Responsibilities 93 Net assets excluding goodwill and intangibles increased to 714.3m 2014: 451.3m Our Financials Adjusted profit before tax of 82.4m 2014: 16.2m, excluding amortisation of intangible assets and reduction in fair value of Oxford Independent auditors report 96 Equity Rights asset of 7.3m 2014: 6.7m Group Primary Statements Net cash and deposits at 31 Dec 2015: 178.8m 2014: 97.3m Consolidated statement of comprehensive income 99 New 8-year 30m debt facility negotiated with European Investment Consolidated statement of Bank financial position 100 Portfolio highlights Consolidated statement of cash flows 101 Fair value of portfolio: 552.2m 2014: 349.9m Consolidated statement of Net increase in fair value of portfolio, excluding net investment, of changes in equity 102 86.2m 2014: 22.3m Group Notes Capital provided to portfolio companies and projects: 75.9m 2014: Notes to the consolidated 46.8m financial statements 103 Portfolio realisations: 0.6m 2014: 9.7m Company Statements Oxford Nanopore completed 70m private financing and its MinION Company balance sheet 135 product became fully commercially available Statement of changes in equity 136 Diurnal Group plc completed 30m AIM admission and began Phase 3 Notes to the Company trials for its Infacort product financial statements 137 Company information IBC In addition to acquisition of 40.0m strategic holding in Oxford Sciences Innovation plc Disclaimer: This Annual Report and Accounts may contain forward-looking statements.
These statements reflect the Boards current view, are subject to a number of material risks and uncertainties and could change in the future.
Factors that could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors relating to the financial or commercial prospects or performance of individual companies within the Groups portfolio.
Further details can be found in the Risk management section on pages 34 to 41.
Throughout this Annual Report and Accounts, the Groups holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.
